Recursion Pharmaceuticals, Inc. RXRX
3.59 USD 0.00 (+0.00%)
At closeNov 12, 2026, 9:01 AM EST
3.46 -0.13 -3.63%
Pre-market · Nov 12, 9:01 AM ET
Day range unavailable
2.77 52-week range 5.24
- YTD
- -12.22%
- 1 year
- -22.80%
Benzinga news
benzinga.com Recursion Appoints Fred Hassan As Board Chair, Effective Oct. 31 Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair,…
benzinga.com ParaZero Technologies To Provide Earnings Updates And REC-4881 Data As Well As KOL And Patient Panels On Tuesday, November 3, 2026 Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, announced today it will provide business…- benzinga.com Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
benzinga.com Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.
benzinga.com Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027 Recursion Announces Sanofi Options Potential First-in-Class Immunology Development CandidateOn October 15, 2026, Recursion announced that Sanofi has optioned the first development candidate from the…
benzinga.com Recursion Commences $200M Common Stock Offering Of 61,540,000 Shares Of Its Class A Common Stock At A Price Of $3.25/Share Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced a $200 million underwritten…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Squeeze Watch: 10 Stocks With Over 33% Short Interest Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
benzinga.com Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new…
benzinga.com Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is…
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss' Cramer likes Vistra and Constellation, but not NextEra. Recursion and Fastly reported weak earnings, Huntington raised sales guidance.- benzinga.com Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over…
benzinga.com Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A decline, signaling a shift in AI adoption.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, Recursion and Twist.
benzinga.com Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
benzinga.com Palo Alto, Fiverr International, Axcelis Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Earnings Scheduled For November 5, 2025 
benzinga.com WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday 
benzinga.com Morgan Stanley, T1 Energy, Bunge Global, Bank of America And Other Big Stocks Moving Higher On Wednesday 
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - benzinga.com Earnings Scheduled For August 5, 2025
benzinga.com Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
benzinga.com Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday 
benzinga.com Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Why Is Microcap Rallybio Stock Trading Higher On Tuesday? Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
benzinga.com Recursion Acquires Rallybio's Full Interest In Joint ENPP1 Inhibitor Program And Associated Backup Molecule For Treatment Of Hypophosphatasia; Rallybio To Receive $7.5M Upfront, With Potential For $17.5M More In Preclinical And Clinical Milestones Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint…- benzinga.com Earnings Scheduled For May 5, 2025
benzinga.com Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
benzinga.com Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday 
benzinga.com Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing…
benzinga.com Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."- benzinga.com Earnings Scheduled For February 28, 2025
benzinga.com Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - benzinga.com SoftBank Group 13F Update: New 14.67M Share Stake In Recursion Pharmaceuticals, 20.45M Shares In Pacific Biosciences, 628.55K Shares In Better Home & Finance; Dissolved 5.68M Shares Stake In Exscientia, 1.59M Shares In IonQ, 23.38K Shares In DoorDash; Increased Stakes in T-Mobile, Nvidia, Webtoon, VTEX, YMM; Decreased Stakes In Lemonade, Nu Holdings, Neumora, Symbotic https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml
benzinga.com Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket 
benzinga.com Nio, Unity Software And Other Big Stocks Moving Higher On Thursday - benzinga.com XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
- benzinga.com Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
- benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Nasdaq Dips Over 2%; US Construction Spending Falls In July
- benzinga.com Market-Moving News for June 27th CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M…
benzinga.com Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session